nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—lung cancer—esophageal cancer	0.405	1	CtDrD
Gefitinib—SBK1—esophageal cancer	0.253	0.627	CbGaD
Gefitinib—CHEK2—esophageal cancer	0.0989	0.245	CbGaD
Gefitinib—EGFR—esophageal cancer	0.0395	0.0979	CbGaD
Gefitinib—ABCG2—Carboplatin—esophageal cancer	0.0157	0.235	CbGbCtD
Gefitinib—ABCG2—Cisplatin—esophageal cancer	0.0135	0.201	CbGbCtD
Gefitinib—ABCB1—esophageal cancer	0.012	0.0298	CbGaD
Gefitinib—CYP2C9—Capecitabine—esophageal cancer	0.00993	0.148	CbGbCtD
Gefitinib—ABCG2—Methotrexate—esophageal cancer	0.00873	0.131	CbGbCtD
Gefitinib—ALB—Methotrexate—esophageal cancer	0.00602	0.09	CbGbCtD
Gefitinib—CYP2C9—Cisplatin—esophageal cancer	0.005	0.0747	CbGbCtD
Gefitinib—ABCB1—Cisplatin—esophageal cancer	0.00485	0.0725	CbGbCtD
Gefitinib—ABCB1—Methotrexate—esophageal cancer	0.00315	0.0471	CbGbCtD
Gefitinib—Skin fissures—Capecitabine—esophageal cancer	0.0021	0.0623	CcSEcCtD
Gefitinib—ERBB3—exocrine gland—esophageal cancer	0.00143	0.0619	CbGeAlD
Gefitinib—Pulmonary toxicity—Cisplatin—esophageal cancer	0.00131	0.039	CcSEcCtD
Gefitinib—Alveolitis—Methotrexate—esophageal cancer	0.00131	0.0388	CcSEcCtD
Gefitinib—Paronychia—Methotrexate—esophageal cancer	0.000944	0.028	CcSEcCtD
Gefitinib—Gastrointestinal perforation—Capecitabine—esophageal cancer	0.000843	0.025	CcSEcCtD
Gefitinib—Oral pain—Capecitabine—esophageal cancer	0.000843	0.025	CcSEcCtD
Gefitinib—Pulmonary toxicity—Methotrexate—esophageal cancer	0.000721	0.0214	CcSEcCtD
Gefitinib—Necrolysis epidermal—Methotrexate—esophageal cancer	0.000721	0.0214	CcSEcCtD
Gefitinib—CHEK2—lung—esophageal cancer	0.000648	0.028	CbGeAlD
Gefitinib—CSNK1E—bronchus—esophageal cancer	0.000636	0.0275	CbGeAlD
Gefitinib—IRAK4—bronchus—esophageal cancer	0.000626	0.0271	CbGeAlD
Gefitinib—ERBB3—epithelium—esophageal cancer	0.000624	0.0269	CbGeAlD
Gefitinib—MKNK2—epithelium—esophageal cancer	0.000593	0.0256	CbGeAlD
Gefitinib—MKNK2—bronchus—esophageal cancer	0.000584	0.0252	CbGeAlD
Gefitinib—IRAK1—bronchus—esophageal cancer	0.000584	0.0252	CbGeAlD
Gefitinib—MKNK1—bronchus—esophageal cancer	0.000577	0.0249	CbGeAlD
Gefitinib—CSNK1E—trachea—esophageal cancer	0.000571	0.0247	CbGeAlD
Gefitinib—MKNK2—smooth muscle tissue—esophageal cancer	0.000571	0.0247	CbGeAlD
Gefitinib—IRAK1—smooth muscle tissue—esophageal cancer	0.000571	0.0247	CbGeAlD
Gefitinib—IRAK4—trachea—esophageal cancer	0.000563	0.0243	CbGeAlD
Gefitinib—ERBB3—trachea—esophageal cancer	0.000551	0.0238	CbGeAlD
Gefitinib—MAP3K19—lung—esophageal cancer	0.000528	0.0228	CbGeAlD
Gefitinib—MKNK2—trachea—esophageal cancer	0.000524	0.0226	CbGeAlD
Gefitinib—SBK1—lymph node—esophageal cancer	0.000508	0.022	CbGeAlD
Gefitinib—Febrile neutropenia—Cisplatin—esophageal cancer	0.000496	0.0147	CcSEcCtD
Gefitinib—CSNK1E—digestive system—esophageal cancer	0.000492	0.0212	CbGeAlD
Gefitinib—Lapatinib—ERBB2—esophageal cancer	0.00048	0.127	CrCbGaD
Gefitinib—STK10—bronchus—esophageal cancer	0.000475	0.0205	CbGeAlD
Gefitinib—ERBB3—digestive system—esophageal cancer	0.000474	0.0205	CbGeAlD
Gefitinib—MKNK2—digestive system—esophageal cancer	0.000451	0.0195	CbGeAlD
Gefitinib—Bosutinib—CSNK1A1—esophageal cancer	0.000449	0.119	CrCbGaD
Gefitinib—Rectal disorder—Capecitabine—esophageal cancer	0.000448	0.0133	CcSEcCtD
Gefitinib—MKNK1—digestive system—esophageal cancer	0.000445	0.0192	CbGeAlD
Gefitinib—CHEK2—lymph node—esophageal cancer	0.000443	0.0191	CbGeAlD
Gefitinib—EGFR—lung—esophageal cancer	0.000427	0.0184	CbGeAlD
Gefitinib—MAP2K5—bronchus—esophageal cancer	0.000424	0.0183	CbGeAlD
Gefitinib—Anorectal disorder—Capecitabine—esophageal cancer	0.000418	0.0124	CcSEcCtD
Gefitinib—CSNK1E—lung—esophageal cancer	0.000411	0.0177	CbGeAlD
Gefitinib—IRAK4—lung—esophageal cancer	0.000404	0.0175	CbGeAlD
Gefitinib—ERBB3—lung—esophageal cancer	0.000396	0.0171	CbGeAlD
Gefitinib—MAP2K5—trachea—esophageal cancer	0.000381	0.0164	CbGeAlD
Gefitinib—Gastric ulcer—Capecitabine—esophageal cancer	0.000378	0.0112	CcSEcCtD
Gefitinib—MKNK2—lung—esophageal cancer	0.000377	0.0163	CbGeAlD
Gefitinib—IRAK1—lung—esophageal cancer	0.000377	0.0163	CbGeAlD
Gefitinib—MKNK1—lung—esophageal cancer	0.000372	0.0161	CbGeAlD
Gefitinib—STK10—digestive system—esophageal cancer	0.000367	0.0158	CbGeAlD
Gefitinib—Febrile neutropenia—Capecitabine—esophageal cancer	0.000366	0.0109	CcSEcCtD
Gefitinib—Infection—Carboplatin—esophageal cancer	0.000361	0.0107	CcSEcCtD
Gefitinib—Hypomagnesaemia—Capecitabine—esophageal cancer	0.000346	0.0103	CcSEcCtD
Gefitinib—Tenderness—Cisplatin—esophageal cancer	0.000342	0.0102	CcSEcCtD
Gefitinib—Afatinib—ERBB2—esophageal cancer	0.000341	0.0898	CrCbGaD
Gefitinib—Keratitis—Capecitabine—esophageal cancer	0.000339	0.0101	CcSEcCtD
Gefitinib—Nail disorder—Capecitabine—esophageal cancer	0.000339	0.0101	CcSEcCtD
Gefitinib—Interstitial pneumonia—Methotrexate—esophageal cancer	0.000339	0.0101	CcSEcCtD
Gefitinib—Appetite absent—Methotrexate—esophageal cancer	0.000329	0.00977	CcSEcCtD
Gefitinib—Ulcer—Cisplatin—esophageal cancer	0.000315	0.00937	CcSEcCtD
Gefitinib—Bosutinib—MAP3K3—esophageal cancer	0.000311	0.0821	CrCbGaD
Gefitinib—Pain—Carboplatin—esophageal cancer	0.00031	0.00922	CcSEcCtD
Gefitinib—STK10—lung—esophageal cancer	0.000306	0.0132	CbGeAlD
Gefitinib—Haemoptysis—Capecitabine—esophageal cancer	0.000297	0.00882	CcSEcCtD
Gefitinib—EGFR—lymph node—esophageal cancer	0.000292	0.0126	CbGeAlD
Gefitinib—Pleural effusion—Capecitabine—esophageal cancer	0.000287	0.00853	CcSEcCtD
Gefitinib—Body temperature increased—Carboplatin—esophageal cancer	0.000287	0.00852	CcSEcCtD
Gefitinib—CSNK1E—lymph node—esophageal cancer	0.000281	0.0121	CbGeAlD
Gefitinib—IRAK4—lymph node—esophageal cancer	0.000276	0.0119	CbGeAlD
Gefitinib—MAP2K5—lung—esophageal cancer	0.000274	0.0118	CbGeAlD
Gefitinib—Febrile neutropenia—Methotrexate—esophageal cancer	0.000272	0.00808	CcSEcCtD
Gefitinib—ERBB3—lymph node—esophageal cancer	0.000271	0.0117	CbGeAlD
Gefitinib—Eruption—Methotrexate—esophageal cancer	0.000266	0.0079	CcSEcCtD
Gefitinib—Afatinib—ABL1—esophageal cancer	0.000265	0.0698	CrCbGaD
Gefitinib—Hypoxia—Methotrexate—esophageal cancer	0.000258	0.00765	CcSEcCtD
Gefitinib—MKNK2—lymph node—esophageal cancer	0.000258	0.0111	CbGeAlD
Gefitinib—IRAK1—lymph node—esophageal cancer	0.000258	0.0111	CbGeAlD
Gefitinib—MKNK1—lymph node—esophageal cancer	0.000254	0.011	CbGeAlD
Gefitinib—Nail disorder—Methotrexate—esophageal cancer	0.000252	0.0075	CcSEcCtD
Gefitinib—Proteinuria—Capecitabine—esophageal cancer	0.00025	0.00743	CcSEcCtD
Gefitinib—Protein urine present—Capecitabine—esophageal cancer	0.000247	0.00733	CcSEcCtD
Gefitinib—Ulcer—Capecitabine—esophageal cancer	0.000233	0.00691	CcSEcCtD
Gefitinib—Interstitial lung disease—Methotrexate—esophageal cancer	0.000231	0.00687	CcSEcCtD
Gefitinib—Lapatinib—EGFR—esophageal cancer	0.000227	0.0599	CrCbGaD
Gefitinib—ORM1—lung—esophageal cancer	0.000222	0.00959	CbGeAlD
Gefitinib—Melaena—Capecitabine—esophageal cancer	0.000215	0.00638	CcSEcCtD
Gefitinib—Pleural effusion—Methotrexate—esophageal cancer	0.000214	0.00635	CcSEcCtD
Gefitinib—Erlotinib—NR1I2—esophageal cancer	0.00021	0.0554	CrCbGaD
Gefitinib—STK10—lymph node—esophageal cancer	0.000209	0.00905	CbGeAlD
Gefitinib—Dry eye—Capecitabine—esophageal cancer	0.000203	0.00603	CcSEcCtD
Gefitinib—Dehydration—Cisplatin—esophageal cancer	0.000201	0.00598	CcSEcCtD
Gefitinib—Mouth ulceration—Capecitabine—esophageal cancer	0.000199	0.00591	CcSEcCtD
Gefitinib—CYP1A1—epithelium—esophageal cancer	0.000199	0.00859	CbGeAlD
Gefitinib—Hypokalaemia—Cisplatin—esophageal cancer	0.000197	0.00585	CcSEcCtD
Gefitinib—CYP1A1—bronchus—esophageal cancer	0.000196	0.00846	CbGeAlD
Gefitinib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000195	0.00579	CcSEcCtD
Gefitinib—CYP2C19—digestive system—esophageal cancer	0.000188	0.00811	CbGeAlD
Gefitinib—MAP2K5—lymph node—esophageal cancer	0.000187	0.00808	CbGeAlD
Gefitinib—Erlotinib—ABL1—esophageal cancer	0.000187	0.0493	CrCbGaD
Gefitinib—Proteinuria—Methotrexate—esophageal cancer	0.000186	0.00553	CcSEcCtD
Gefitinib—Thrombophlebitis—Capecitabine—esophageal cancer	0.000184	0.00548	CcSEcCtD
Gefitinib—Protein urine present—Methotrexate—esophageal cancer	0.000184	0.00546	CcSEcCtD
Gefitinib—Pancreatitis—Cisplatin—esophageal cancer	0.000184	0.00545	CcSEcCtD
Gefitinib—Hepatic failure—Capecitabine—esophageal cancer	0.000178	0.00528	CcSEcCtD
Gefitinib—Eye pain—Capecitabine—esophageal cancer	0.000177	0.00525	CcSEcCtD
Gefitinib—CYP1A1—trachea—esophageal cancer	0.000176	0.0076	CbGeAlD
Gefitinib—Bosutinib—CHEK2—esophageal cancer	0.000175	0.0463	CrCbGaD
Gefitinib—Ulcer—Methotrexate—esophageal cancer	0.000173	0.00514	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000169	0.00502	CcSEcCtD
Gefitinib—Atrial fibrillation—Capecitabine—esophageal cancer	0.000168	0.005	CcSEcCtD
Gefitinib—Dermatitis bullous—Capecitabine—esophageal cancer	0.000167	0.00496	CcSEcCtD
Gefitinib—Respiratory failure—Methotrexate—esophageal cancer	0.000167	0.00495	CcSEcCtD
Gefitinib—Stomatitis—Cisplatin—esophageal cancer	0.000163	0.00483	CcSEcCtD
Gefitinib—Conjunctivitis—Cisplatin—esophageal cancer	0.000162	0.00482	CcSEcCtD
Gefitinib—Afatinib—EGFR—esophageal cancer	0.000161	0.0425	CrCbGaD
Gefitinib—Melaena—Methotrexate—esophageal cancer	0.00016	0.00475	CcSEcCtD
Gefitinib—Cystitis noninfective—Methotrexate—esophageal cancer	0.00016	0.00475	CcSEcCtD
Gefitinib—Cystitis—Methotrexate—esophageal cancer	0.000158	0.0047	CcSEcCtD
Gefitinib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000158	0.00469	CcSEcCtD
Gefitinib—ORM1—lymph node—esophageal cancer	0.000152	0.00656	CbGeAlD
Gefitinib—CYP1A1—digestive system—esophageal cancer	0.000151	0.00653	CbGeAlD
Gefitinib—Dehydration—Capecitabine—esophageal cancer	0.000148	0.00441	CcSEcCtD
Gefitinib—Bladder pain—Methotrexate—esophageal cancer	0.000148	0.0044	CcSEcCtD
Gefitinib—Mouth ulceration—Methotrexate—esophageal cancer	0.000148	0.0044	CcSEcCtD
Gefitinib—Urinary tract disorder—Cisplatin—esophageal cancer	0.000148	0.00439	CcSEcCtD
Gefitinib—CYP3A5—digestive system—esophageal cancer	0.000148	0.00639	CbGeAlD
Gefitinib—Urethral disorder—Cisplatin—esophageal cancer	0.000147	0.00436	CcSEcCtD
Gefitinib—Dry skin—Capecitabine—esophageal cancer	0.000146	0.00435	CcSEcCtD
Gefitinib—CYP2C9—digestive system—esophageal cancer	0.000146	0.00629	CbGeAlD
Gefitinib—Hypokalaemia—Capecitabine—esophageal cancer	0.000145	0.00432	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000144	0.00427	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000144	0.00427	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000141	0.00418	CcSEcCtD
Gefitinib—Eye disorder—Cisplatin—esophageal cancer	0.00014	0.00416	CcSEcCtD
Gefitinib—Cardiac disorder—Cisplatin—esophageal cancer	0.000139	0.00413	CcSEcCtD
Gefitinib—Thrombophlebitis—Methotrexate—esophageal cancer	0.000137	0.00408	CcSEcCtD
Gefitinib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000135	0.00401	CcSEcCtD
Gefitinib—Arrhythmia—Cisplatin—esophageal cancer	0.000134	0.00398	CcSEcCtD
Gefitinib—ALB—lymph node—esophageal cancer	0.000133	0.00575	CbGeAlD
Gefitinib—ABCG2—lung—esophageal cancer	0.000133	0.00575	CbGeAlD
Gefitinib—Alopecia—Cisplatin—esophageal cancer	0.000132	0.00393	CcSEcCtD
Gefitinib—Hepatic failure—Methotrexate—esophageal cancer	0.000132	0.00393	CcSEcCtD
Gefitinib—Malnutrition—Cisplatin—esophageal cancer	0.00013	0.00387	CcSEcCtD
Gefitinib—CYP1A1—lung—esophageal cancer	0.000126	0.00546	CbGeAlD
Gefitinib—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000126	0.00374	CcSEcCtD
Gefitinib—Weight decreased—Capecitabine—esophageal cancer	0.000125	0.00371	CcSEcCtD
Gefitinib—Pneumonia—Capecitabine—esophageal cancer	0.000124	0.00368	CcSEcCtD
Gefitinib—CYP3A5—lung—esophageal cancer	0.000124	0.00534	CbGeAlD
Gefitinib—Vandetanib—ABL1—esophageal cancer	0.000123	0.0325	CrCbGaD
Gefitinib—Infestation—Capecitabine—esophageal cancer	0.000123	0.00365	CcSEcCtD
Gefitinib—Infestation NOS—Capecitabine—esophageal cancer	0.000123	0.00365	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000122	0.00362	CcSEcCtD
Gefitinib—Anaemia—Cisplatin—esophageal cancer	0.000121	0.00358	CcSEcCtD
Gefitinib—Erlotinib—CYP1B1—esophageal cancer	0.000121	0.0318	CrCbGaD
Gefitinib—Stomatitis—Capecitabine—esophageal cancer	0.00012	0.00356	CcSEcCtD
Gefitinib—Conjunctivitis—Capecitabine—esophageal cancer	0.00012	0.00355	CcSEcCtD
Gefitinib—Malaise—Cisplatin—esophageal cancer	0.000118	0.00349	CcSEcCtD
Gefitinib—Haematuria—Capecitabine—esophageal cancer	0.000117	0.00348	CcSEcCtD
Gefitinib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000116	0.00346	CcSEcCtD
Gefitinib—Epistaxis—Capecitabine—esophageal cancer	0.000116	0.00345	CcSEcCtD
Gefitinib—Bosutinib—ABL1—esophageal cancer	0.000115	0.0304	CrCbGaD
Gefitinib—Erlotinib—EGFR—esophageal cancer	0.000114	0.03	CrCbGaD
Gefitinib—CYP3A4—digestive system—esophageal cancer	0.000111	0.00479	CbGeAlD
Gefitinib—Haemoglobin—Capecitabine—esophageal cancer	0.000111	0.0033	CcSEcCtD
Gefitinib—Haemorrhage—Capecitabine—esophageal cancer	0.00011	0.00328	CcSEcCtD
Gefitinib—Hepatitis—Capecitabine—esophageal cancer	0.00011	0.00328	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00011	0.00328	CcSEcCtD
Gefitinib—CYP2D6—digestive system—esophageal cancer	0.000109	0.00472	CbGeAlD
Gefitinib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000109	0.00324	CcSEcCtD
Gefitinib—Oedema peripheral—Capecitabine—esophageal cancer	0.000109	0.00323	CcSEcCtD
Gefitinib—Urethral disorder—Capecitabine—esophageal cancer	0.000108	0.00322	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000107	0.00318	CcSEcCtD
Gefitinib—Infection—Cisplatin—esophageal cancer	0.000106	0.00314	CcSEcCtD
Gefitinib—Vandetanib—KDR—esophageal cancer	0.000105	0.0276	CrCbGaD
Gefitinib—Erythema multiforme—Capecitabine—esophageal cancer	0.000104	0.0031	CcSEcCtD
Gefitinib—Nervous system disorder—Cisplatin—esophageal cancer	0.000104	0.0031	CcSEcCtD
Gefitinib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000104	0.0031	CcSEcCtD
Gefitinib—Skin disorder—Cisplatin—esophageal cancer	0.000103	0.00307	CcSEcCtD
Gefitinib—ABCB1—epithelium—esophageal cancer	0.000103	0.00446	CbGeAlD
Gefitinib—Eye disorder—Capecitabine—esophageal cancer	0.000103	0.00307	CcSEcCtD
Gefitinib—Cardiac disorder—Capecitabine—esophageal cancer	0.000102	0.00304	CcSEcCtD
Gefitinib—Anorexia—Cisplatin—esophageal cancer	0.000101	0.00301	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—esophageal cancer	0.000101	0.00299	CcSEcCtD
Gefitinib—Angiopathy—Capecitabine—esophageal cancer	0.0001	0.00298	CcSEcCtD
Gefitinib—Mediastinal disorder—Capecitabine—esophageal cancer	9.95e-05	0.00296	CcSEcCtD
Gefitinib—Hypotension—Cisplatin—esophageal cancer	9.95e-05	0.00295	CcSEcCtD
Gefitinib—Arrhythmia—Capecitabine—esophageal cancer	9.87e-05	0.00293	CcSEcCtD
Gefitinib—Alopecia—Capecitabine—esophageal cancer	9.76e-05	0.0029	CcSEcCtD
Gefitinib—Malnutrition—Capecitabine—esophageal cancer	9.61e-05	0.00286	CcSEcCtD
Gefitinib—Dyspnoea—Cisplatin—esophageal cancer	9.49e-05	0.00282	CcSEcCtD
Gefitinib—Decreased appetite—Cisplatin—esophageal cancer	9.25e-05	0.00275	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—esophageal cancer	9.21e-05	0.00274	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	9.19e-05	0.00273	CcSEcCtD
Gefitinib—Infestation—Methotrexate—esophageal cancer	9.16e-05	0.00272	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—esophageal cancer	9.16e-05	0.00272	CcSEcCtD
Gefitinib—ABCB1—trachea—esophageal cancer	9.13e-05	0.00395	CbGeAlD
Gefitinib—Pain—Cisplatin—esophageal cancer	9.1e-05	0.0027	CcSEcCtD
Gefitinib—ABCG2—lymph node—esophageal cancer	9.1e-05	0.00393	CbGeAlD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	9.08e-05	0.0027	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—esophageal cancer	8.93e-05	0.00265	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—esophageal cancer	8.9e-05	0.00264	CcSEcCtD
Gefitinib—Anaemia—Capecitabine—esophageal cancer	8.89e-05	0.00264	CcSEcCtD
Gefitinib—Cisapride—CYP2A6—esophageal cancer	8.75e-05	0.0231	CrCbGaD
Gefitinib—Haematuria—Methotrexate—esophageal cancer	8.73e-05	0.00259	CcSEcCtD
Gefitinib—Malaise—Capecitabine—esophageal cancer	8.67e-05	0.00257	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—esophageal cancer	8.66e-05	0.00257	CcSEcCtD
Gefitinib—CYP1A1—lymph node—esophageal cancer	8.64e-05	0.00373	CbGeAlD
Gefitinib—Epistaxis—Methotrexate—esophageal cancer	8.64e-05	0.00257	CcSEcCtD
Gefitinib—Body temperature increased—Cisplatin—esophageal cancer	8.41e-05	0.0025	CcSEcCtD
Gefitinib—Cough—Capecitabine—esophageal cancer	8.39e-05	0.00249	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—esophageal cancer	8.26e-05	0.00245	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—esophageal cancer	8.22e-05	0.00244	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—esophageal cancer	8.22e-05	0.00244	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	8.13e-05	0.00241	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—esophageal cancer	8.12e-05	0.00241	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—esophageal cancer	8.06e-05	0.00239	CcSEcCtD
Gefitinib—Dry mouth—Capecitabine—esophageal cancer	8e-05	0.00238	CcSEcCtD
Gefitinib—ABCB1—digestive system—esophageal cancer	7.86e-05	0.00339	CbGeAlD
Gefitinib—Hypersensitivity—Cisplatin—esophageal cancer	7.84e-05	0.00233	CcSEcCtD
Gefitinib—Infection—Capecitabine—esophageal cancer	7.79e-05	0.00232	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—esophageal cancer	7.77e-05	0.00231	CcSEcCtD
Gefitinib—Shock—Capecitabine—esophageal cancer	7.72e-05	0.00229	CcSEcCtD
Gefitinib—Nervous system disorder—Capecitabine—esophageal cancer	7.69e-05	0.00229	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—esophageal cancer	7.68e-05	0.00228	CcSEcCtD
Gefitinib—Thrombocytopenia—Capecitabine—esophageal cancer	7.68e-05	0.00228	CcSEcCtD
Gefitinib—Asthenia—Cisplatin—esophageal cancer	7.64e-05	0.00227	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—esophageal cancer	7.63e-05	0.00227	CcSEcCtD
Gefitinib—Skin disorder—Capecitabine—esophageal cancer	7.62e-05	0.00226	CcSEcCtD
Gefitinib—Vandetanib—EGFR—esophageal cancer	7.49e-05	0.0198	CrCbGaD
Gefitinib—Anorexia—Capecitabine—esophageal cancer	7.48e-05	0.00222	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—esophageal cancer	7.46e-05	0.00222	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—esophageal cancer	7.41e-05	0.0022	CcSEcCtD
Gefitinib—Hypotension—Capecitabine—esophageal cancer	7.33e-05	0.00218	CcSEcCtD
Gefitinib—Diarrhoea—Cisplatin—esophageal cancer	7.28e-05	0.00216	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—esophageal cancer	7.26e-05	0.00216	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—esophageal cancer	7.16e-05	0.00213	CcSEcCtD
Gefitinib—Bosutinib—EGFR—esophageal cancer	7.01e-05	0.0185	CrCbGaD
Gefitinib—Dyspnoea—Capecitabine—esophageal cancer	7e-05	0.00208	CcSEcCtD
Gefitinib—Lapatinib—ABCB1—esophageal cancer	6.91e-05	0.0182	CrCbGaD
Gefitinib—Decreased appetite—Capecitabine—esophageal cancer	6.82e-05	0.00203	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	6.77e-05	0.00201	CcSEcCtD
Gefitinib—Vomiting—Cisplatin—esophageal cancer	6.77e-05	0.00201	CcSEcCtD
Gefitinib—Fatigue—Capecitabine—esophageal cancer	6.76e-05	0.00201	CcSEcCtD
Gefitinib—Rash—Cisplatin—esophageal cancer	6.71e-05	0.00199	CcSEcCtD
Gefitinib—Pain—Capecitabine—esophageal cancer	6.71e-05	0.00199	CcSEcCtD
Gefitinib—Constipation—Capecitabine—esophageal cancer	6.71e-05	0.00199	CcSEcCtD
Gefitinib—Dermatitis—Cisplatin—esophageal cancer	6.7e-05	0.00199	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—esophageal cancer	6.61e-05	0.00196	CcSEcCtD
Gefitinib—ABCB1—lung—esophageal cancer	6.56e-05	0.00283	CbGeAlD
Gefitinib—Malaise—Methotrexate—esophageal cancer	6.45e-05	0.00192	CcSEcCtD
Gefitinib—Gastrointestinal pain—Capecitabine—esophageal cancer	6.42e-05	0.00191	CcSEcCtD
Gefitinib—Nausea—Cisplatin—esophageal cancer	6.32e-05	0.00188	CcSEcCtD
Gefitinib—Cough—Methotrexate—esophageal cancer	6.25e-05	0.00185	CcSEcCtD
Gefitinib—Urticaria—Capecitabine—esophageal cancer	6.23e-05	0.00185	CcSEcCtD
Gefitinib—Body temperature increased—Capecitabine—esophageal cancer	6.2e-05	0.00184	CcSEcCtD
Gefitinib—Abdominal pain—Capecitabine—esophageal cancer	6.2e-05	0.00184	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	6.05e-05	0.0018	CcSEcCtD
Gefitinib—Infection—Methotrexate—esophageal cancer	5.8e-05	0.00172	CcSEcCtD
Gefitinib—Hypersensitivity—Capecitabine—esophageal cancer	5.78e-05	0.00172	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—esophageal cancer	5.73e-05	0.0017	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—esophageal cancer	5.72e-05	0.0017	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—esophageal cancer	5.67e-05	0.00169	CcSEcCtD
Gefitinib—Asthenia—Capecitabine—esophageal cancer	5.63e-05	0.00167	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—esophageal cancer	5.57e-05	0.00165	CcSEcCtD
Gefitinib—Pruritus—Capecitabine—esophageal cancer	5.55e-05	0.00165	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—esophageal cancer	5.46e-05	0.00162	CcSEcCtD
Gefitinib—Diarrhoea—Capecitabine—esophageal cancer	5.37e-05	0.00159	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—esophageal cancer	5.21e-05	0.00155	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—esophageal cancer	5.08e-05	0.00151	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	5.04e-05	0.0015	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—esophageal cancer	5.04e-05	0.0015	CcSEcCtD
Gefitinib—Pain—Methotrexate—esophageal cancer	4.99e-05	0.00148	CcSEcCtD
Gefitinib—Vomiting—Capecitabine—esophageal cancer	4.99e-05	0.00148	CcSEcCtD
Gefitinib—Rash—Capecitabine—esophageal cancer	4.95e-05	0.00147	CcSEcCtD
Gefitinib—Dermatitis—Capecitabine—esophageal cancer	4.94e-05	0.00147	CcSEcCtD
Gefitinib—Afatinib—ABCB1—esophageal cancer	4.9e-05	0.0129	CrCbGaD
Gefitinib—Gastrointestinal pain—Methotrexate—esophageal cancer	4.78e-05	0.00142	CcSEcCtD
Gefitinib—Nausea—Capecitabine—esophageal cancer	4.66e-05	0.00138	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—esophageal cancer	4.64e-05	0.00138	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—esophageal cancer	4.62e-05	0.00137	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—esophageal cancer	4.62e-05	0.00137	CcSEcCtD
Gefitinib—ABCB1—lymph node—esophageal cancer	4.49e-05	0.00194	CbGeAlD
Gefitinib—Hypersensitivity—Methotrexate—esophageal cancer	4.3e-05	0.00128	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—esophageal cancer	4.19e-05	0.00124	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—esophageal cancer	4.13e-05	0.00123	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—esophageal cancer	4e-05	0.00119	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—esophageal cancer	3.71e-05	0.0011	CcSEcCtD
Gefitinib—Rash—Methotrexate—esophageal cancer	3.68e-05	0.00109	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—esophageal cancer	3.68e-05	0.00109	CcSEcCtD
Gefitinib—Nausea—Methotrexate—esophageal cancer	3.47e-05	0.00103	CcSEcCtD
Gefitinib—Erlotinib—ABCB1—esophageal cancer	3.46e-05	0.00912	CrCbGaD
Gefitinib—Bosutinib—ABCB1—esophageal cancer	2.13e-05	0.00562	CrCbGaD
Gefitinib—CYP2C9—Metabolism—TPI1—esophageal cancer	2.66e-06	4.2e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTO1—esophageal cancer	2.66e-06	4.2e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CDKN1A—esophageal cancer	2.65e-06	4.2e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ALDH2—esophageal cancer	2.65e-06	4.19e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NOTCH1—esophageal cancer	2.64e-06	4.18e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GAPDH—esophageal cancer	2.62e-06	4.15e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.62e-06	4.15e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CRABP1—esophageal cancer	2.6e-06	4.12e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ENO1—esophageal cancer	2.59e-06	4.09e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS1—esophageal cancer	2.59e-06	4.09e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EGFR—esophageal cancer	2.58e-06	4.09e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NOS3—esophageal cancer	2.58e-06	4.08e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EP300—esophageal cancer	2.57e-06	4.07e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALDOB—esophageal cancer	2.57e-06	4.07e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PSME2—esophageal cancer	2.55e-06	4.03e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PSME1—esophageal cancer	2.55e-06	4.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOS2—esophageal cancer	2.55e-06	4.03e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALDOB—esophageal cancer	2.55e-06	4.03e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GNG7—esophageal cancer	2.53e-06	4.01e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.53e-06	4.01e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFBR2—esophageal cancer	2.53e-06	4.01e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EP300—esophageal cancer	2.52e-06	3.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOTCH1—esophageal cancer	2.52e-06	3.99e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTT1—esophageal cancer	2.52e-06	3.98e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ERBB2—esophageal cancer	2.5e-06	3.96e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CASP8—esophageal cancer	2.49e-06	3.94e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP2A6—esophageal cancer	2.49e-06	3.94e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CA2—esophageal cancer	2.49e-06	3.94e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.48e-06	3.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CREBBP—esophageal cancer	2.48e-06	3.92e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GNG7—esophageal cancer	2.47e-06	3.91e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GAPDH—esophageal cancer	2.47e-06	3.91e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GAPDH—esophageal cancer	2.45e-06	3.88e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CRABP1—esophageal cancer	2.45e-06	3.88e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—PIK3CA—esophageal cancer	2.45e-06	3.87e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MYC—esophageal cancer	2.44e-06	3.86e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NOS3—esophageal cancer	2.44e-06	3.86e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CRABP1—esophageal cancer	2.43e-06	3.85e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—ERBB2—esophageal cancer	2.41e-06	3.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SMAD4—esophageal cancer	2.4e-06	3.79e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CREBBP—esophageal cancer	2.4e-06	3.79e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EGFR—esophageal cancer	2.38e-06	3.77e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALDH2—esophageal cancer	2.37e-06	3.76e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—esophageal cancer	2.37e-06	3.75e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS1—esophageal cancer	2.36e-06	3.73e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ENO1—esophageal cancer	2.36e-06	3.73e-05	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.36e-06	3.73e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GNG7—esophageal cancer	2.33e-06	3.69e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP1B1—esophageal cancer	2.33e-06	3.68e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PSME2—esophageal cancer	2.32e-06	3.68e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PSME1—esophageal cancer	2.32e-06	3.68e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALDH2—esophageal cancer	2.32e-06	3.67e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLCE1—esophageal cancer	2.31e-06	3.66e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ADH7—esophageal cancer	2.31e-06	3.66e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GNG7—esophageal cancer	2.31e-06	3.66e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CREBBP—esophageal cancer	2.29e-06	3.62e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTT1—esophageal cancer	2.26e-06	3.57e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—PIK3CA—esophageal cancer	2.24e-06	3.55e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MYC—esophageal cancer	2.24e-06	3.55e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP2A6—esophageal cancer	2.23e-06	3.53e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.23e-06	3.52e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.22e-06	3.52e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCND1—esophageal cancer	2.21e-06	3.5e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTT1—esophageal cancer	2.2e-06	3.49e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP1B1—esophageal cancer	2.2e-06	3.48e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EGFR—esophageal cancer	2.19e-06	3.47e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP19A1—esophageal cancer	2.19e-06	3.46e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALDH2—esophageal cancer	2.18e-06	3.46e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.18e-06	3.45e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALDH2—esophageal cancer	2.17e-06	3.43e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EGFR—esophageal cancer	2.15e-06	3.4e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NOS3—esophageal cancer	2.14e-06	3.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—PIK3CA—esophageal cancer	2.14e-06	3.39e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CDKN1A—esophageal cancer	2.14e-06	3.38e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—BCL2—esophageal cancer	2.14e-06	3.38e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCND1—esophageal cancer	2.13e-06	3.37e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ENO1—esophageal cancer	2.12e-06	3.35e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS1—esophageal cancer	2.12e-06	3.35e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PSME1—esophageal cancer	2.09e-06	3.3e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PSME2—esophageal cancer	2.09e-06	3.3e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTT1—esophageal cancer	2.08e-06	3.29e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ERBB2—esophageal cancer	2.07e-06	3.28e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PIK3CA—esophageal cancer	2.07e-06	3.28e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP19A1—esophageal cancer	2.07e-06	3.27e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ENO1—esophageal cancer	2.07e-06	3.27e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS1—esophageal cancer	2.07e-06	3.27e-05	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.06e-06	3.27e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTT1—esophageal cancer	2.06e-06	3.26e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CDKN1A—esophageal cancer	2.06e-06	3.26e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—PIK3CA—esophageal cancer	2.06e-06	3.26e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP2A6—esophageal cancer	2.05e-06	3.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOS3—esophageal cancer	2.05e-06	3.24e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP2A6—esophageal cancer	2.04e-06	3.22e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PSME2—esophageal cancer	2.04e-06	3.22e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PSME1—esophageal cancer	2.04e-06	3.22e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EP300—esophageal cancer	2.03e-06	3.22e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.03e-06	3.21e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.03e-06	3.21e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.03e-06	3.21e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ERBB2—esophageal cancer	2.01e-06	3.17e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP1B1—esophageal cancer	2e-06	3.17e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—HMOX1—esophageal cancer	2e-06	3.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HIF1A—esophageal cancer	1.96e-06	3.1e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EP300—esophageal cancer	1.96e-06	3.1e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.95e-06	3.08e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ENO1—esophageal cancer	1.95e-06	3.08e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMP—esophageal cancer	1.94e-06	3.07e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ENO1—esophageal cancer	1.93e-06	3.05e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.93e-06	3.05e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PSME2—esophageal cancer	1.92e-06	3.04e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PSME1—esophageal cancer	1.92e-06	3.04e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ABCB1—esophageal cancer	1.92e-06	3.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—ERBB2—esophageal cancer	1.92e-06	3.03e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PIK3CA—esophageal cancer	1.9e-06	3.01e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PSME2—esophageal cancer	1.9e-06	3.01e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PSME1—esophageal cancer	1.9e-06	3.01e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—HMOX1—esophageal cancer	1.89e-06	2.99e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP19A1—esophageal cancer	1.89e-06	2.98e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.88e-06	2.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KDR—esophageal cancer	1.88e-06	2.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—esophageal cancer	1.87e-06	2.96e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PIK3CA—esophageal cancer	1.87e-06	2.95e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—EP300—esophageal cancer	1.85e-06	2.93e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.85e-06	2.93e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—esophageal cancer	1.84e-06	2.91e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.84e-06	2.91e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.82e-06	2.88e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ABCB1—esophageal cancer	1.81e-06	2.87e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP1B1—esophageal cancer	1.8e-06	2.85e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CREBBP—esophageal cancer	1.79e-06	2.83e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDKN1A—esophageal cancer	1.77e-06	2.81e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—esophageal cancer	1.77e-06	2.8e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—esophageal cancer	1.77e-06	2.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOTCH1—esophageal cancer	1.77e-06	2.8e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.76e-06	2.78e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TPI1—esophageal cancer	1.75e-06	2.77e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.75e-06	2.77e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—esophageal cancer	1.73e-06	2.74e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—HMOX1—esophageal cancer	1.72e-06	2.72e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CDKN1A—esophageal cancer	1.71e-06	2.71e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—esophageal cancer	1.71e-06	2.7e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP19A1—esophageal cancer	1.69e-06	2.68e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.69e-06	2.67e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—EP300—esophageal cancer	1.69e-06	2.67e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.68e-06	2.66e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—esophageal cancer	1.67e-06	2.64e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.66e-06	2.63e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.66e-06	2.62e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.65e-06	2.61e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ABCB1—esophageal cancer	1.65e-06	2.61e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.64e-06	2.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN1A—esophageal cancer	1.64e-06	2.59e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EP300—esophageal cancer	1.63e-06	2.58e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.62e-06	2.56e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.6e-06	2.54e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CREBBP—esophageal cancer	1.6e-06	2.53e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NOS3—esophageal cancer	1.6e-06	2.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—EP300—esophageal cancer	1.56e-06	2.47e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.56e-06	2.46e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.54e-06	2.44e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.54e-06	2.44e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNG7—esophageal cancer	1.52e-06	2.41e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.51e-06	2.4e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HMOX1—esophageal cancer	1.51e-06	2.39e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—esophageal cancer	1.5e-06	2.38e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.48e-06	2.35e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—esophageal cancer	1.46e-06	2.32e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—esophageal cancer	1.45e-06	2.3e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—esophageal cancer	1.45e-06	2.29e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—esophageal cancer	1.43e-06	2.27e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.43e-06	2.26e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—esophageal cancer	1.42e-06	2.25e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.42e-06	2.25e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.41e-06	2.23e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—esophageal cancer	1.4e-06	2.22e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—esophageal cancer	1.39e-06	2.2e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.38e-06	2.19e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—esophageal cancer	1.37e-06	2.17e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.37e-06	2.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—esophageal cancer	1.37e-06	2.16e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.36e-06	2.16e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.36e-06	2.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—esophageal cancer	1.36e-06	2.15e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.35e-06	2.14e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.34e-06	2.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—esophageal cancer	1.34e-06	2.12e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—esophageal cancer	1.33e-06	2.1e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.28e-06	2.03e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO1—esophageal cancer	1.27e-06	2.01e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.27e-06	2.01e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PSME2—esophageal cancer	1.25e-06	1.99e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PSME1—esophageal cancer	1.25e-06	1.99e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.25e-06	1.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—esophageal cancer	1.25e-06	1.98e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—EP300—esophageal cancer	1.22e-06	1.93e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CREBBP—esophageal cancer	1.21e-06	1.92e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—esophageal cancer	1.21e-06	1.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—esophageal cancer	1.19e-06	1.88e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—esophageal cancer	1.17e-06	1.85e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—esophageal cancer	1.15e-06	1.82e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—esophageal cancer	1.15e-06	1.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1A—esophageal cancer	1.15e-06	1.81e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.12e-06	1.77e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CREBBP—esophageal cancer	1.1e-06	1.75e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EP300—esophageal cancer	1.09e-06	1.73e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—esophageal cancer	1.08e-06	1.72e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.08e-06	1.71e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—esophageal cancer	1.05e-06	1.66e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.02e-06	1.62e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.02e-06	1.61e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—esophageal cancer	9.91e-07	1.57e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CREBBP—esophageal cancer	9.91e-07	1.57e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—esophageal cancer	9.88e-07	1.56e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CREBBP—esophageal cancer	9.67e-07	1.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—esophageal cancer	9.51e-07	1.5e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	9.29e-07	1.47e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CREBBP—esophageal cancer	9.11e-07	1.44e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—esophageal cancer	9.04e-07	1.43e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CREBBP—esophageal cancer	9.03e-07	1.43e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—esophageal cancer	9.01e-07	1.43e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	8.91e-07	1.41e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—esophageal cancer	8.87e-07	1.4e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—EP300—esophageal cancer	8.73e-07	1.38e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—esophageal cancer	8.66e-07	1.37e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—EP300—esophageal cancer	8.24e-07	1.3e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—esophageal cancer	8.16e-07	1.29e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—esophageal cancer	8.11e-07	1.28e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—esophageal cancer	8.09e-07	1.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—esophageal cancer	8.07e-07	1.28e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—esophageal cancer	7.92e-07	1.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—esophageal cancer	7.81e-07	1.24e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—EP300—esophageal cancer	7.52e-07	1.19e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—esophageal cancer	7.46e-07	1.18e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—esophageal cancer	7.4e-07	1.17e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—EP300—esophageal cancer	6.75e-07	1.07e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—EP300—esophageal cancer	6.58e-07	1.04e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—esophageal cancer	6.46e-07	1.02e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—EP300—esophageal cancer	6.21e-07	9.82e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—EP300—esophageal cancer	6.15e-07	9.74e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—esophageal cancer	6.1e-07	9.65e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.96e-07	9.43e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—esophageal cancer	5.56e-07	8.8e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—esophageal cancer	5.33e-07	8.44e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—esophageal cancer	4.99e-07	7.9e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.88e-07	7.72e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—esophageal cancer	4.87e-07	7.71e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.59e-07	7.26e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—esophageal cancer	4.55e-07	7.2e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—EP300—esophageal cancer	4.06e-07	6.42e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3e-07	4.75e-06	CbGpPWpGaD
